Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Large Cap Fund median (41 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 30 Jun 2015 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 100 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | JM Large Cap Fund |
|---|---|
| 30 Jun 2015 | ₹100.00 |
| 03 Jun 2016 | ₹99.15 |
| 08 May 2017 | ₹110.55 |
| 12 Apr 2018 | ₹119.86 |
| 17 Mar 2019 | ₹125.07 |
| 19 Feb 2020 | ₹130.65 |
| 24 Jan 2021 | ₹158.50 |
| 29 Dec 2021 | ₹192.21 |
| 03 Dec 2022 | ₹206.52 |
| 07 Nov 2023 | ₹230.27 |
| 11 Oct 2024 | ₹324.75 |
| 15 Sep 2025 | ₹314.20 |
| 20 Aug 2026 | ₹322.32 |
| Metric | JM Financial · Direct · IDCW NAV ₹74.30 Very High risk ★★★★☆ | Category median Large Cap Fund · 41 funds |
|---|---|---|
| +3.19% | -3.12% | |
| +13.31% | +9.35% | |
| +12.55% | +8.00% | |
| +12.01% | +7.97% | |
| +11.08% | +9.16% | |
| +11.14% | — | |
| +13.58% | +10.38% | |
| +13.90% | +9.26% | |
| +12.50% | +8.80% | |
| Risk | ||
| 14.98% | 14.48% | |
| 0.46 | 0.16 | |
| 0.62 | 0.21 | |
| -19.80% | -36.60% | |
| Nifty 100 | — | |
| +2.97% | +0.11% | |
| 1.01 | 0.98 | |
| 111.5% | 96.8% | |
| 98.3% | 98.3% | |
| 1.18% | 1.08% | |
| ₹417.88Cr | ₹1,495Cr | |
| 1.00% | — | |
| None | — | |
| ₹100 | — | |
| ₹1.00K | — | |
| 124% | 58% | |
| Ruchi Fozdar | — | |
| 30 Jun 2015 | — | |
| 49 | — | |
| 37.7% | — | |
| 3.0% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.